OBJECTIVE: Knee pain from osteoarthritis is frequent in the adult population. Prior trials have had conflicting results concerning the therapeutic effects of vitamin D on knee pain, and few trials have investigated marine Omega-3 fatty acids (n-3 FA). METHODS: In the double-blind, placebo-controlled Vitamin D and Omega-3 Trial (VITAL), 25,871 US adults were randomized in a 2-by-2 factorial design to receive vitamin D or n-3 FA. We identified a subgroup with chronic knee pain prior to randomization and assessed knee pain at baseline and annually during follow-up using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) (graded on a 0-100 scale, where 100 indicates worst symptoms). Repeated measures modeling was used to test the effect of randomized treatment on WOMAC pain scores over follow-up after adjustment for age and sex. Analyses were repeated for WOMAC function and stiffness. RESULTS: This study included 1,398 participants who returned at least one knee pain questionnaire. The mean age was 67.7 years, 66% were women, and the mean ± SD WOMAC pain score was 37 ± 19. The mean ± SD follow-up time was 5.3 ± 0.7 years. WOMAC pain did not differ between the active vitamin D group and the vitamin D placebo group or between the active n-3 FA group and the n-3 FA placebo group at any time point during follow-up. Linear time-by-treatment interactions were not significant for either treatment (vitamin D, P = 0.41; n-3 FA, P = 0.77). Vitamin D and n-3 FA supplementation did not significantly affect WOMAC function or stiffness scores over time. CONCLUSION: Our findings indicate that vitamin D and n-3 FA supplementation for a mean of 5.3 years does not reduce knee pain or improve function or stiffness in a large sample of US adults with chronic knee pain.
OBJECTIVE: Knee pain from osteoarthritis is frequent in the adult population. Prior trials have had conflicting results concerning the therapeutic effects of vitamin D on knee pain, and few trials have investigated marine Omega-3 fatty acids (n-3 FA). METHODS: In the double-blind, placebo-controlled Vitamin D and Omega-3 Trial (VITAL), 25,871 US adults were randomized in a 2-by-2 factorial design to receive vitamin D or n-3 FA. We identified a subgroup with chronic knee pain prior to randomization and assessed knee pain at baseline and annually during follow-up using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) (graded on a 0-100 scale, where 100 indicates worst symptoms). Repeated measures modeling was used to test the effect of randomized treatment on WOMAC pain scores over follow-up after adjustment for age and sex. Analyses were repeated for WOMAC function and stiffness. RESULTS: This study included 1,398 participants who returned at least one knee pain questionnaire. The mean age was 67.7 years, 66% were women, and the mean ± SD WOMAC pain score was 37 ± 19. The mean ± SD follow-up time was 5.3 ± 0.7 years. WOMAC pain did not differ between the active vitamin D group and the vitamin D placebo group or between the active n-3 FA group and the n-3 FA placebo group at any time point during follow-up. Linear time-by-treatment interactions were not significant for either treatment (vitamin D, P = 0.41; n-3 FA, P = 0.77). Vitamin D and n-3 FA supplementation did not significantly affect WOMAC function or stiffness scores over time. CONCLUSION: Our findings indicate that vitamin D and n-3 FA supplementation for a mean of 5.3 years does not reduce knee pain or improve function or stiffness in a large sample of US adults with chronic knee pain.
Authors: JoAnn E Manson; Nancy R Cook; I-Min Lee; William Christen; Shari S Bassuk; Samia Mora; Heike Gibson; David Gordon; Trisha Copeland; Denise D'Agostino; Georgina Friedenberg; Claire Ridge; Vadim Bubes; Edward L Giovannucci; Walter C Willett; Julie E Buring Journal: N Engl J Med Date: 2018-11-10 Impact factor: 91.245
Authors: JoAnn E Manson; Nancy R Cook; I-Min Lee; William Christen; Shari S Bassuk; Samia Mora; Heike Gibson; Christine M Albert; David Gordon; Trisha Copeland; Denise D'Agostino; Georgina Friedenberg; Claire Ridge; Vadim Bubes; Edward L Giovannucci; Walter C Willett; Julie E Buring Journal: N Engl J Med Date: 2018-11-10 Impact factor: 91.245
Authors: Bhushan R Deshpande; Jeffrey N Katz; Daniel H Solomon; Edward H Yelin; David J Hunter; Stephen P Messier; Lisa G Suter; Elena Losina Journal: Arthritis Care Res (Hoboken) Date: 2016-11-03 Impact factor: 4.794
Authors: Laura L Laslett; Stephen Quinn; John R Burgess; Venkateswaran Parameswaran; Tania M Winzenberg; Graeme Jones; Changhai Ding Journal: Ann Rheum Dis Date: 2013-04-17 Impact factor: 19.103
Authors: Shari S Bassuk; JoAnn E Manson; I-Min Lee; Nancy R Cook; William G Christen; Vadim Y Bubes; David S Gordon; Trisha Copeland; Georgina Friedenberg; Denise M D'Agostino; Claire Y Ridge; Jean G MacFadyen; Kate Kalan; Julie E Buring Journal: Contemp Clin Trials Date: 2016-01-06 Impact factor: 2.226
Authors: Akemi T Wijayabahu; Angela M Mickle; Volker Mai; Cynthia Garvan; Toni L Glover; Robert L Cook; Jinying Zhao; Marianna K Baum; Roger B Fillingim; Kimberly T Sibille Journal: Nutrients Date: 2022-01-09 Impact factor: 5.717